Open Access Highly Accessed Research article

Is overexpression of HER-2 a predictor of prognosis in colorectal cancer?

Dara O Kavanagh*, Gillian Chambers, Liam O' Grady, Kevin M Barry, Ronan P Waldron, Fadel Bennani, Paul W Eustace and Iqdam Tobbia

BMC Cancer 2009, 9:1  doi:10.1186/1471-2407-9-1

PubMed Commons is an experimental system of commenting on PubMed abstracts, introduced in October 2013. Comments are displayed on the abstract page, but during the initial closed pilot, only registered users can read or post comments. Any researcher who is listed as an author of an article indexed by PubMed is entitled to participate in the pilot. If you would like to participate and need an invitation, please email info@biomedcentral.com, giving the PubMed ID of an article on which you are an author. For more information, see the PubMed Commons FAQ.

Targeting EGFR, HER2 and VEGF

Michael H��lling   (2009-01-23 11:10)  Roche Pharma AG email

Dear Sir,<br><br>my first comment is just a technical one, as for the time being the provisional pdf of the article is not accessible.<br><br>Secondly, in the abstract the monoclonal antibody (MAB)Bevacizumab is erroneously described as targeting the human epidermal growth factor receptor (EGFR), while in fact it targets the vascular endothelial growth factor (VEGF) (but not its receptor). The MAB targeting the EGFR is named Cetuximab.<br><br>Yours faithfully<br>Michael Hölling

Competing interests

Roche: employee

top

Post a comment